Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis
Company To Initially Target 70 Cancer Centers
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
